119 lines
46 KiB
Text
119 lines
46 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK547958">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK547958/?report=reader">
|
|
<meta name="ncbi_pagename" content="Glycopeptide Antibiotics - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Glycopeptide Antibiotics - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Glucosamine/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Glycopyrrolate/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Glycopeptide Antibiotics">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2017/11/12">
|
|
<meta name="citation_pmid" content="31643291">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK547958/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Glycopeptide Antibiotics">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2017/11/12">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK547958/">
|
|
<meta name="description" content="The glycopeptide antibiotics are semisynthetic macromolecules that are structurally related to vancomycin and have antibacterial activity against several gram positive organisms including methicillin resistant Staphylococcus aureus (MRSA). Three lipoglycopeptide antibiotics are available for use in the United States: dalbavancin, oritavancin and telavancin. All three agents have been associated with transient serum enzyme elevations during therapy, but they have yet to be linked convincingly to cases of clinically apparent acute liver injury.">
|
|
<meta name="og:title" content="Glycopeptide Antibiotics">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="The glycopeptide antibiotics are semisynthetic macromolecules that are structurally related to vancomycin and have antibacterial activity against several gram positive organisms including methicillin resistant Staphylococcus aureus (MRSA). Three lipoglycopeptide antibiotics are available for use in the United States: dalbavancin, oritavancin and telavancin. All three agents have been associated with transient serum enzyme elevations during therapy, but they have yet to be linked convincingly to cases of clinically apparent acute liver injury.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK547958/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/GlycopeptideAntibiot/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK547958/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8C66F77D7D57B100000000003D0039.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK547958/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Glucosamine/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Glycopeptide Antibiotics</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Glycopyrrolate/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK547958/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK547958/&text=Glycopeptide%20Antibiotics"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK547958/?report=classic">Switch to classic view</a><a href="/books/NBK547958/pdf/Bookshelf_NBK547958.pdf">PDF (185K)</a><a href="/books/NBK547958/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK547958%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8C66F77D7D57B100000000003D0039.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK547958_"><span class="title" itemprop="name">Glycopeptide Antibiotics</span></h1><p class="fm-aai"><a href="#_NBK547958_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><p>DALBAVANCIN, ORITAVANCIN, TELAVANCIN</p><div id="GlycopeptideAntibiot.OVERVIEW"><h2 id="_GlycopeptideAntibiot_OVERVIEW_">OVERVIEW</h2><div id="GlycopeptideAntibiot.Introduction"><h3>Introduction</h3><p>The glycopeptide antibiotics are semisynthetic macromolecules that are structurally related to vancomycin and have antibacterial activity against several gram positive organisms including methicillin resistant Staphylococcus aureus (MRSA). Three lipoglycopeptide antibiotics are available for use in the United States: dalbavancin, oritavancin and telavancin. All three agents have been associated with transient serum enzyme elevations during therapy, but they have yet to be linked convincingly to cases of clinically apparent acute liver injury.</p></div><div id="GlycopeptideAntibiot.Background"><h3>Background</h3><p>The glycopeptide antibiotics are a class of antimicrobial agents that share a similar, macromolecular structure and basic mechanism of action. The lipoglycopeptides are largely synthetic derivatives of vancomycin modified to have greater potency or better pharmacokinetics and tolerance. Like vancomycin, these agents have potent antibacterial activity against several Streptococcus and Enterococcus species as well as Staphylococcus aureus, including strains that are methicillin-resistant (MRSA). The agents are macromolecular glycopeptides that act by binding to nascent bacterial cell wall peptidoglycans, thus interfering with cell wall synthesis. The lipoglycopeptides are not absorbed orally and have a prolonged half-life when given intravenously which allows for once daily and, in some cases, once weekly administration. Vancomycin is a similar glycopeptide, but its indications, wide scale use and record of safety are greater than the more recently approved lipoglycopeptide derivatives. Vancomycin is discussed in a separate document in LiverTox. Three lipoglycopeptide antibiotics have been approved for use in the United States and are discussed together: telavancin (2009), dalbavancin (2014) and oritavancin (2014).</p><p>Telavancin (tel" a van' sin) is a macromolecular semisynthetic lipoglycopeptide with potent antimicrobial activity against several gram positive organisms including Staphylococcus aureus. The activity of telavancin against methicillin-resistant S. aureus (MRSA) infections has made it a valuable agent in the management of community and nosocomial acquired severe MRSA related infections. Telavancin was approved for use in the United States in 2009 for severe infections of the skin and skin structures due to susceptible organisms, and the indications were subsequently broadened to therapy of severe nosocomial pneumonia. Telavancin is available in solution in single use vials of 250 and 750 mg under the commercial name Vibativ. The recommended dose in adults is 10 mg/kg intravenously given over a 60 minute period once daily for 7 to 21 days. Side effects include infusion reactions, nausea, diarrhea, taste disturbance and foamy urine. Telavancin can also cause renal dysfunction and prolongation of the QTc interval. Rare side effects include hypersensitivity reactions, renal failure and Clostridium difficile (pseudomembranous) colitis.</p><p>Dalbavancin (dal" ba van' sin) is a macromolecular semisynthetic lipoglycopeptide with potent spectrum of antimicrobial activity against several gram positive organisms including Staphylococcus aureus. The activity of dalbavancin against MRSA infections has made it a valuable agent in the management of community and nosocomial acquired severe MRSA related infections. Dalbavancin was approved for use in the United States in 2014 for severe skin and skin structure infections due to susceptible organisms including MRSA. It is available as a powder for suspension in vials of 500 mg under the commercial name Dalvance. The recommended dose in adults is a single infusion of 1000 mg given intravenously over a 30 minute period, followed one week later by 500 mg intravenously. It can also be given as a single 1500 mg intravenous infusion. Side effects can include infusion reactions (“red man syndrome”), headache, nausea, diarrhea, rash and pruritus. Rare side effects include hypersensitivity reactions and Clostridium difficile (pseudomembranous) colitis.</p><p>Oritavancin (or it" a van' sin) is a macromolecular semisynthetic lipoglycopeptide with potent antimicrobial activity against several gram positive organisms including Staphylococcus aureus. The activity of oritavancin against MRSA infections has made it a valuable agent in the management of community and nosocomial acquired severe MRSA-related infections. Oritavancin was approved for use in the United States in 2014 for severe skin and skin structure infections due to susceptible organisms including MRSA. It is available as a sterile powder for suspension in single use vials of 400 mg under the commercial name Orbactiv. The recommended dose in adults is a single infusion of 1200 mg intravenously over a 3 hour period. Side effects include infusion reactions, headache, nausea, diarrhea, skin rash and pruritus. Rare side effects include hypersensitivity reactions and Clostridium difficile (pseudomembranous) colitis.</p></div><div id="GlycopeptideAntibiot.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In prelicensure controlled trials, serum ALT elevations during therapy with dalbvancin, oritavancin or telavancin were common, occurring in up to 25% of patients. Serum aminotransferase elevations above three times the upper limit of normal, however, were uncommon, occurring in 0.8% to 6% of patients receiving dalbavancin, oritavancin or telavancin. Furthermore, these rates of liver test abnormalities were not very different from those in comparator arms. The ALT elevations during glycopeptide antibiotic therapy were in general transient, asymptomatic and only mild-to-moderate in severity, rarely leading to dose modifications or early discontinuations. There were no reports of clinically apparent liver injury with jaundice in the registration trials of these agents. Since their approval and more wide scale use, there have been no published reports of liver injury attributed to glycopeptide antibiotics, although hypersensitivity reactions have been reported which can sometimes be associated with a mild-to-moderate degree of liver injury. Regardless, these three agents are relatively new, have not been widely used and when used, are given for a relatively short period of time and none have been linked to serious cases of liver injury.</p><p>Likelihood score: E (unlikely causes of clinically apparent liver injury).</p></div><div id="GlycopeptideAntibiot.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism of the serum aminotransferase elevations and mild liver injury that can occur during intravenous therapy with glycopeptide antibiotics is not known. All three of the currently available lipoglycopeptides have only minor hepatic metabolism and they have no or only weak effects on the activity of the microsomal cytochrome P450 enzymes.</p></div><div id="GlycopeptideAntibiot.Outcome_and_Managem"><h3>Outcome and Management</h3><p>The serum enzyme elevations that occur during dalbavancin, oritavancin and telavancin therapy are generally mild and self-limited and rarely require dose modification. There have been no reports of acute liver failure, chronic hepatitis or vanishing bile duct syndrome associated with the glycopeptide antibiotics. There is likely to be some degree of cross sensitivity to the acute hypersensitivity reactions that can occur with infusions of the different glycopeptides.</p><p>Drug Class: <a href="/books/n/livertox/Antiinfective/?report=reader">Antiinfective Agents</a></p><p>Other Drugs in the Subclass, Glycopeptide Antibiotics: Vancomycin</p></div></div><div id="GlycopeptideAntibiot.PRODUCT_INFORMATION"><h2 id="_GlycopeptideAntibiot_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="GlycopeptideAntibiot.BPI" class="box boxed-text-box whole_rhythm hide-overflow"><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Dalbavancin – Dalvance®</p><p>Oritavancin – Orbactiv®</p><p>Telavancin – Vibativ®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Antineoplastic Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Glycopeptide%20Antibiotics" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="GlycopeptideAntibiot.CHEMICAL_FORMULAS_A"><h2 id="_GlycopeptideAntibiot_CHEMICAL_FORMULAS_A_">CHEMICAL FORMULAS AND STRUCTURES</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figGlycopeptideAntibiotT1"><a href="/books/NBK547958/table/GlycopeptideAntibiot.T1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figGlycopeptideAntibiotT1" rid-ob="figobGlycopeptideAntibiotT1"><img class="small-thumb" src="/books/NBK547958/table/GlycopeptideAntibiot.T1/?report=thumb" src-large="/books/NBK547958/table/GlycopeptideAntibiot.T1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="GlycopeptideAntibiot.T1"><a href="/books/NBK547958/table/GlycopeptideAntibiot.T1/?report=objectonly" target="object" rid-ob="figobGlycopeptideAntibiotT1">Table</a></h4></div></div></div><div id="GlycopeptideAntibiot.ANNOTATED_BIBLIOGRA"><h2 id="_GlycopeptideAntibiot_ANNOTATED_BIBLIOGRA_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 12 November 2017</p><ul class="first-line-outdent"><li><div class="bk_ref" id="GlycopeptideAntibiot.R1">Moseley RH. Vancomycin. Hepatotoxicity of antimicrobials and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced Liver Disease. 3rd edition. Amsterdam: Elsevier, 2013, p. 469.<div><i>(Expert review of antibiotic induced liver injury discusses vancomycin, but not the other glycopeptide antibiotics).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R2">MacDougall C, Chambers HF. Protein synthesis inhibitors and miscellaneous antibacterial agents. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1521-47.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R3">Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 2008; 46: 577-83. [<a href="https://pubmed.ncbi.nlm.nih.gov/18199045" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18199045</span></a>]<div><i>(Review of the mechanism of action, efficacy and safety of dalbavancin mentions that it has been used in more than 1000 patients and “there is no known evidence of renal or hepatic toxicity”).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R4">Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, et al.; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46: 1683-93. [<a href="https://pubmed.ncbi.nlm.nih.gov/18444791" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18444791</span></a>]<div><i>(Among 1867 patients with severe bacterial skin or skin structure infections treated with telavancin or vancomycin, clinical cure rates were similar [88% vs 87%] and common side effects included taste disturbance [33% vs 7%], nausea [27% vs 15%], headache [14% vs 13%], foamy urine [13% vs 3%], renal dysfunction [3% vs 1%], ALT elevations above 3 times ULN [2% vs 4%] and increase in QTc [1.2% vs 0.6%]).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R5">Telavancin (Vibativ) for gram-positive skin infections. Med Lett Drugs Ther 2010; 52 (1329): 1-2. [<a href="https://pubmed.ncbi.nlm.nih.gov/20208468" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20208468</span></a>]<div><i>(Concise summary of the mechanism of action, clinical efficacy, side effects and costs of telavancin shortly after its approval in the US, mentions common side effects of nausea, diarrhea, renal dysfunction and taste disturbance and rare side effects of renal failure [~3%] and prolongation of the QTc interval).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R6">Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, et al.; ATTAIN Study Group. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011; 52: 31-40. [<a href="/pmc/articles/PMC3060890/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3060890</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21148517" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21148517</span></a>]<div><i>(Among 1503 patients with severe hospital acquired pneumonia treated with telavancin [10 mg/kg/day] or vancomycin [1 g every 12 hours] for 7-21 days, cure rates were similar [59% vs 59.5%], creatinine elevations occurred in 16% vs 10% and ALT elevations above 3 times ULN in 6% vs 8%).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R7">Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014; 370: 2169-79. [<a href="https://pubmed.ncbi.nlm.nih.gov/24897082" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24897082</span></a>]<div><i>(Among 1312 patients with acute skin and skin structure infections treated with dalbavancin [day 1 and 8] or vancomycin [days 1-3] with an option to receive oral linezolid [days 4-14], clinical response rates were similar [80% vs 80%] and common side effects included nausea, diarrhea and pruritus; ALT elevations occurred in 23% of both groups but were usually mild, being above 3 times ULN occurred in 1.4% vs 0.2% of patients).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R8">Two new drugs for skin and skin structure infections. Med Lett Drugs Ther 2014; 56 (1449): 73-5. [<a href="https://pubmed.ncbi.nlm.nih.gov/25118799" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25118799</span></a>]<div><i>(Concise review of the mechanism of action, efficacy, safety and cost of dalbavancin therapy shortly after its approval in the US mentions side effects of nausea, diarrhea, headache and infusion reactions [“red man syndrome”]; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R9">Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, Giordano P, et al.; SOLO I Investigators. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014 Jun 5; 370 (23): 2180-90. [<a href="https://pubmed.ncbi.nlm.nih.gov/24897083" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24897083</span></a>]<div><i>(Among 954 patients with severe bacterial skin and skin structure infections treated with oritavancin [single 1200 mg dose] or vancomycin [twice daily for 7 to 10 days], clinical cure rates were similar [80% vs 80%] as were adverse event rates; abnormal liver tests occurred in 2.3% of oritavancin vs 1.0% of vancomycin treated subjects, but none developed clinically apparent liver injury with jaundice).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R10">Barriere SL. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future Microbiol 2014; 9: 281-9. [<a href="https://pubmed.ncbi.nlm.nih.gov/24450506" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24450506</span></a>]<div><i>(Among 1532 patients with severe hospital acquired pneumonia treated with telavancin vs vancomycin, cure rates were similar [58% vs 59%] but all-cause mortality was higher with telavancin [39% vs 30%], while side effect rates were similar; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R11">Oritavancin (Orbactiv) for skin and skin structure infections. Med Lett Drugs Ther 2015; 57 (1459): 3-5. [<a href="https://pubmed.ncbi.nlm.nih.gov/25555072" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25555072</span></a>]<div><i>(Concise summary of the mechanism of action, clinical efficacy, safety and costs of oritavancin shortly after its approval in the US for severe skin infections, mentions common side effects of nausea [10%], headache [7%] and diarrhea [4%], and that it does not have the renal and disturbed taste side effects of telavancin).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R12">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7. [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 3 cases were attributed to vancomycin, but none to the other glycopeptide antibiotics).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R13">Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis 2016; 62: 545-51. [<a href="/pmc/articles/PMC4741365/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4741365</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26611777" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26611777</span></a>]<div><i>(Among 698 patients with skin or skin structure bacterial infections treated with 1500 mg of dalbavancin as either a single or as two infusions one week apart, the clinical response rates were similar [81% vs 84%] and adverse events rates were the same [20% vs 20%]; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R14">Dunne MW, Talbot GH, Boucher HW, Wilcox M, Puttagunta S. Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies. Drug Saf 2016; 39: 147-57. [<a href="/pmc/articles/PMC4735234/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4735234</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26715497" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26715497</span></a>]<div><i>(Among 1778 patients with skin or skin structure bacterial infections treated with dalbavancin and 1224 who received comparator agents in phase 2 and 3 studies, common side effects of dalbavancin included nausea [5.5% vs 6.4%], headache [4.7% vs 4.8%], diarrhea [4.4% vs 5.9%], rash [2% vs 1.8%] and pruritus [1.8% vs 2.9%]; ALT abnormalities of any degree occurred in 24% vs 26% of subjects and were above 3 times ULN in 2.6% vs 2.6%; no patient developed clinically apparent liver injury with jaundice).</i></div></div></li><li><div class="bk_ref" id="GlycopeptideAntibiot.R15">Bassetti M, Righi E. Safety profiles of old and new antimicrobials for the treatment of MRSA infections. Expert Opin Drug Saf 2016; 15 (4): 467-81. [<a href="https://pubmed.ncbi.nlm.nih.gov/26764972" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26764972</span></a>]<div><i>(Summary and overview of the safety of recently developed drugs for MRSA infections including telavancin, dalbavancin and oritavancin mentions transient ALT elevations during therapy, but no mention of clinically apparent hepatotoxicity).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK547958_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">November 12, 2017</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Glycopeptide Antibiotics. [Updated 2017 Nov 12].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Glucosamine/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Glycopyrrolate/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="boxed-text" id="figobGlycopeptideAntibiotBPI"><div id="GlycopeptideAntibiot.BPI" class="box boxed-text-box whole_rhythm hide-overflow"><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Dalbavancin – Dalvance®</p><p>Oritavancin – Orbactiv®</p><p>Telavancin – Vibativ®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Antineoplastic Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Glycopeptide%20Antibiotics" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></article><article data-type="table-wrap" id="figobGlycopeptideAntibiotT1"><div id="GlycopeptideAntibiot.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547958/table/GlycopeptideAntibiot.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__GlycopeptideAntibiot.T1_lrgtbl__"><table><thead><tr><th id="hd_h_GlycopeptideAntibiot.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_GlycopeptideAntibiot.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_GlycopeptideAntibiot.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_GlycopeptideAntibiot.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Dalbavancin</td><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135109743" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">171500-79-1</a>
|
|
</td><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C88-H100-Cl2-N10-O28</td><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK547958/bin/Dalbavancin_structure.jpg" alt="Dalbavancin chemical structure" /></div>
|
|
</td></tr><tr><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Oritavancin</td><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135154684" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">171099-57-3</a>
|
|
</td><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C80-H106-Cl2-N11-O27-P</td><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK547958/bin/Oritavancin_structure.jpg" alt="Oritavancin chemical structure" /></div>
|
|
</td></tr><tr><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Telavancin</td><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135228307" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">372151-71-8</a>
|
|
</td><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C80-H106-Cl2-N11-O27-P</td><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK547958/bin/Telavancin_structure.jpg" alt="Telavancin chemical structure" /></div>
|
|
</td></tr><tr><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Vancomycin</td><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134980842" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">1404-90-6</a>
|
|
</td><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C66-H75-C12-N9-O24</td><td headers="hd_h_GlycopeptideAntibiot.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK547958/bin/Vancomycin_Structure.jpg" alt="Vancomycin chemical structure" /></div>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|